In 2004, S-J Choi et al. reported the results of a prospective study evaluating the efficacy of etoposide, cytarabine, idarubicin, and G-CSF followed by G-CSF-primed DLI in patients with advanced myeloid malignancy who relapsed after allo-HSCT [13]. Here, CSF3 is linked to myeloid neoplasm.